BCL2 and B-cell chronic lymphocytic leukemia: Venetoclax, a selective Bcl‐2 inhibitor, further reduced exhaustion without impairing CAR T‐cell viability, likely through enhanced target cell elimination rather than direct modulation of CAR T‐cell biology, supporting current trials combining Venetoclax with CAR T therapy in CLL (NCT03331198).